Condition: Neoplasm - Soft Tissue Pelvis Malignant Secondary · Malignant Neoplasm of Stomach · Sponsor: Fox Chase Cancer Center
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
This description comes directly from the study's public registry record.
Tanu Singh · 12152141439 · tanu.singh@fccc.edu
Joshua Meyer, MD · 215-728-2667 · Joshua.Meyer@fccc.edu
Always discuss trial participation with your own doctor first.
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05880667